Revealing Stage I Cancer Through Microbiome-Driven Liquid Biopsy™
Empowering clinicians and saving patient lives with early-stage diagnosis through minimally invasive microbiome-driven liquid biopsy™
“There are more microbes in the human body than there are stars in the Universe. With this much information to tackle, we are converging advances in the understanding of cancer, microbiome, molecular technologies, and big data science into new, exciting capabilities to diagnose disease early and save lives. We have a line of sight on powerful new solutions that will revolutionize the standard of care.”
Sandrine Miller-Montgomery, CEO & Co-Founder of Micronoma
The diagnostic implications of microbiome markers in tissue and liquid biopsies are endless. As the only cancer diagnostic company using the microbiome to detect early-stage cancer, Micronoma has the cutting-edge advantage.
Our patent pending Oncobiota™ platform reveals the cancer-related microbiome with unparalleled specificity and sensitivity. Our minimally invasive and precise microbiome-driven liquid biopsy™ method can detect cancer in its earliest stages, unlike tests that only focus on the human genome, epigenome, or cancer mutations.
Oncobiota™ can be applied to many cancer types. Starting with lung cancer, which has the highest need for early detection in terms of incidence and mortality rates, we can make a big difference in the lives of the many patients affected each year.
Advantages Over Traditional Liquid Biopsy
A liquid biopsy is a test done on a sample of blood to look for a methylation or fragmentation profile and/or within circulating tumor cells (CTC) and/or DNA that is shed from the tumor.
However, to detect these signals, a large enough tumor mass is required, which prevents the reliable possibility of accurate cancer detection in its earliest stages.
At Micronoma, we focus on the circulating microbial nucleic acid signatures present from the tumor and the body’s response to the developing tumor. Importantly, these signals are not dependent on tumor size, enabling our proprietary platform to detect cancer at an earlier stage of development.
“Our novel method to detect specific microbiome biomarkers in a simple blood draw offers a revolutionary new option for early cancer detection.”
Rob Knight, PhD, Co-Founder of Micronoma
Humans and Microbes
Humans and microbes co-exist in a mutually beneficial relationship in our bodies. Microbes can be found naturally not only in our stools, but also in our mouths, tissues, and blood, even when we are healthy.
The microbiome is the community of all the microbes—bacteria, fungi, protozoa, and viruses—that live on and inside the human body. The composition of the microbiome changes with many factors such as location in the body, lifestyle, and gender. If analyzed properly, the microbiome can reveal the status of our health.
Microbes and Cancer
Microbes are now known to be found in human tissues, including cancer tissues and blood. Micronoma’s proprietary platform and global expertise allow for the identification of microbial signatures in circulating blood that are predictive of a cancerous tumor. This minimally invasive liquid biopsy sample type can be more easily collected than a solid tissue sample.
Micronoma, a San Diego company, says its technology picks up signs of very early cancer from disrupted microbiome. Many researchers and companies are chasing the dream of detecting biomarkers of solid tumors in the blood, either to guide treatment, discover the cancer...
World Vaccine Immunotherapy Congress West Coast 2021. Nov 30- Dec 2, 2021
6th Microbiome Movement Drug Development Summit. January 25-27, 2022
Precision Medicine World Conference 2022. 1/26-1/28 2022 - "Cancer Microbiome and Diagnostic Application"
Translational Microbiome Conference. April 13-14, 2022
9th Microbiome R&D and Business Collaboration Forum. March 29-30, 2022.